Tenorio syndrome: Description of 14 novel cases and review of the clinical and molecular features.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
10 2021
Historique:
revised: 24 06 2021
received: 05 04 2021
accepted: 28 06 2021
pubmed: 2 7 2021
medline: 1 2 2022
entrez: 1 7 2021
Statut: ppublish

Résumé

Tenorio syndrome (TNORS) (OMIM #616260) is a relatively recent disorder with very few cases described so far. Clinical features included macrocephaly, intellectual disability, hypotonia, enlarged ventricles and autoimmune diseases. Molecular underlying mechanism demonstrated missense variants and a large deletion encompassing RNF125, a gene that encodes for an U3 ubiquitin ligase protein. Since the initial description of the disorder in six patients from four families, several new patients were diagnosed, adding more evidence to the clinical spectrum. In this article, we described 14 additional cases with deep phenotyping and make an overall review of all the cases with pathogenic variants in RNF125. Not all patients presented with overgrowth, but instead, most patients showed a common pattern of neurodevelopmental disease, macrocephaly and/or large forehead. Segregation analysis showed that, though the variant was inherited in some patients from an apparently asymptomatic parent, deep phenotyping suggested a mild form of the disease in some of them. The mechanism underlying the development of this disease is not well understood yet and the report of further cases will help to a better understanding and clinical characterization of the syndrome.

Identifiants

pubmed: 34196401
doi: 10.1111/cge.14020
doi:

Substances chimiques

RNF125 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

405-411

Subventions

Organisme : Federación Española de Enfermedades Raras (FEDER)
ID : PI20

Informations de copyright

© 2021 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.

Références

Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet. 2005;137C:53-71.
Tenorio J, Mansilla A, Valencia M, et al. A new overgrowth syndrome is due to mutations in RNF125. Hum Mutat. 2014;35:1436-1441.
Biesecker LG, Sapp JC. Proteus Syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews([R]). Seattle (WA); 1993.
Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167A:287-295.
Gordo G, Tenorio J, Arias P, et al. mTOR mutations in smith-Kingsmore syndrome: four additional patients and a review. Clin Genet. 2018;93:762-775.
Rademacher S, Eickholt BJ. PTEN in autism and neurodevelopmental disorders. Cold Spring Harb Perspect Med. 2019;9:a036780.
Chen J, Alberts I, Li X. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders. Int J Dev Neurosci. 2014;35:35-41.
Borrie SC, Brems H, Legius E, Bagni C. Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. Annu Rev Genomics Hum Genet. 2017;18:115-142.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928-930.
Tenorio J, Alarcon P, Arias P, et al. Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients. Eur J Human Genet. 2020;28:469-479.
Tenorio J, Alarcon P, Arias P, et al. MRX93 syndrome (BRWD3 gene): five new patients with novel mutations. Clin Genet. 2019;95:726-731.
Nevado J, Rosenfeld JA, Mena R, et al. PIAS4 is associated with macro/microcephaly in the novel interstitial 19p13.3 microdeletion/microduplication syndrome. Eur J Human Genet. 2015;23:1615-1626.
Tenorio J, Nevado J, Gonzalez-Meneses A, et al. Further definition of the proximal 19p13.3 microdeletion/microduplication syndrome and implication of PIAS4 as the major contributor. Clin Genet. 2020;97:467-476.
Liu ZY, Cao J, Zhang JT, et al. Ring finger protein 125, as a potential highly aggressive and unfavorable prognostic biomarker, promotes the invasion and metastasis of human gallbladder cancers via activating the TGF- beta1-SMAD3-ID1 signaling pathway. Oncotarget. 2017;8:49897-49914.
Frints SGM, Ozanturk A, Rodriguez Criado G, et al. Pathogenic variants in E3 ubiquitin ligase RLIM/RNF12 lead to a syndromic X-linked intellectual disability and behavior disorder. Mol Psychiatry. 2019;24:1748-1768.
Santens P, Van Damme T, Steyaert W, et al. RNF216 mutations as a novel cause of autosomal recessive Huntington-like disorder. Neurology. 2015;84:1760-1766.
Stewart GS, Panier S, Townsend K, et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell. 2009;136:420-434.
Edvardson S, Nicolae CM, Noh GJ, et al. Heterozygous RNF13 gain-of-function variants are associated with congenital microcephaly, epileptic encephalopathy, blindness, and failure to thrive. Am J Hum Genet. 2019;104:179-185.
Smol T, Petit F, Piton A, et al. MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype. Neurogenetics. 2018;19:93-103.

Auteurs

Jair Antonio Tenorio-Castaño (JA)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Overgrowth Syndromes Laboratory, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Ithaca, European Reference Network, Brussels, Belgium.

Pedro Arias (P)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Overgrowth Syndromes Laboratory, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Alberto Fernández-Jaén (A)

Hospital Universitario Quirónsalud Madrid, Universidad Europea de Madrid, Spain.

Guillermo Lay-Son (G)

Unidad de Genética, División de Pediatría, Facultad de Medicina, Pontificia Universidad Católica de, Chile.

Gloria Bueno-Lozano (G)

Unit of Clinical Genetics, Service of Paediatrics, School of Medicine, University Hospital 'Lozano Blesa, University of Zaragoza, CIBERER-GCV02 and ISS-Aragón, Zaragoza, Spain.

Allan Bayat (A)

Department of Pediatrics, Hvidovre Hospital, University of Copenhagen, Denmark.

Laurence Faivre (L)

Ithaca, European Reference Network, Brussels, Belgium.
Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.
UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France.

Natalia Gallego (N)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Overgrowth Syndromes Laboratory, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Ithaca, European Reference Network, Brussels, Belgium.

Sergio Ramos (S)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Overgrowth Syndromes Laboratory, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Kameryn M Butler (KM)

Cytogenetics Laboratory, Greenwood Genetic Center, Greenwood, South Carolina, USA.

Chantal Morel (C)

University Health Network, Fred A. Litwin Family Centre in Genetic Medicine, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Stasia Hadjiyannakis (S)

Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.

James Lespinasse (J)

Service de Cytogenetique, Centre Hospitalier de Chambéry, Chambéry, France.

Frederic Tran-Mau-Them (F)

UF6254 Innovation en Diagnostic Genomique des Maladies Rares Bat, Pôle de Biologie, CHU, Dijon, France.

Fernando Santos-Simarro (F)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Ithaca, European Reference Network, Brussels, Belgium.
Clinical Genetics section, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Lucile Pinson (L)

Départment de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CHU de Montpellier, Montpellier, France.

Antonio Federico Martínez-Monseny (AF)

Clinical Genetics section, Department of Genetic and Molecular Medicine and Pediatric Institute of Rare Diseases (IPER), Hospital Sant Joan de Déu, Barcelona, Spain.
Department of Pediatric Neurology, Hospital Sant Joan de Déu, Barcelona, Spain.

María Del Mar O'Callaghan Cord (MDM)

Clinical Genetics section, Department of Genetic and Molecular Medicine and Pediatric Institute of Rare Diseases (IPER), Hospital Sant Joan de Déu, Barcelona, Spain.

Sara Álvarez (S)

NIMGENETICS, Calle de Anabel Segura, Madrid, Spain.

Elliot S Stolerman (ES)

Cytogenetics Laboratory, Greenwood Genetic Center, Greenwood, South Carolina, USA.

Camerun Washington (C)

Cytogenetics Laboratory, Greenwood Genetic Center, Greenwood, South Carolina, USA.

Feliciano J Ramos (FJ)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Unit of Clinical Genetics, Service of Paediatrics, School of Medicine, University Hospital 'Lozano Blesa, University of Zaragoza, CIBERER-GCV02 and ISS-Aragón, Zaragoza, Spain.
Unit of Pediatric Endocrinology, Service of Paediatrics, University Hospital Lozano Blesa, Zaragoza, Spain.
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Overgrowth Syndromes Laboratory, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Pablo Lapunzina (P)

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Overgrowth Syndromes Laboratory, INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario la Paz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Ithaca, European Reference Network, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH